Literature DB >> 16243431

High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand.

V Sriuranpong1, C Chantranuwat, N Huapai, T Chalermchai, K Leungtaweeboon, P Lertsanguansinchai, N Voravud, A Mutirangura.   

Abstract

Recent reports have suggested influences of racial difference on the frequency of mutation of EGFR in lung cancer. We therefore sought to characterize the frequency and pattern of mutation of EGFR in lung adenocarcinoma in Thai patients. Overall, EGFR catalytic domain mutations were detected in 35/61 (57.4%). We found 29/60 (48.3%) of exon 19 deletions, 5/54 (9.3%) of exon 21 point mutations, and 1/54 (1.9%) of double-mutation of both exons. The presence of these mutations was significantly associated with non-smoking habit. In summary, we report a strikingly high prevalence of mutation of EGFR in Thai lung adenocarcinoma, which may explain the high response rate to the treatment with TKI among Asian populations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16243431     DOI: 10.1016/j.canlet.2005.08.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

1.  Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China.

Authors:  Ablajan Abdurahman; Jurat Anwar; Abdugheni Turghun; Madiniyet Niyaz; Liwei Zhang; Idiris Awut
Journal:  Mol Clin Oncol       Date:  2015-05-11

2.  Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma.

Authors:  Ming-Hsien Li; Jo-Ting Tsai; Lai-Lei Ting; Jang-Chun Lin; Yu-Chang Liu
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

3.  Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report.

Authors:  Makoto Ogata; Toshiki Shimizu; Takashi Yokoi; Shosaku Nomura
Journal:  J Med Case Rep       Date:  2011-11-22

4.  Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer.

Authors:  Sutima Luangdilok; Passakorn Wanchaijiraboon; Poonchavist Chantranuwatana; Chinachote Teerapakpinyo; Shanop Shuangshoti; Virote Sriuranpong
Journal:  Transl Lung Cancer Res       Date:  2019-12

5.  Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study.

Authors:  Krittiya Korphaisarn; Pongwut Danchaivijitr; Thanyanan Reungwetwattana; Busayamas Chewaskulyong; Luangyot Thongthieang; Jarin Chindaprasirt; Kunlatida Maneenil; Chirawadee Sathitruangsak; Chanida Vinayanuwattikun
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

6.  Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014.

Authors:  Joanne T Chang; Jihyoun Jeon; Hutcha Sriplung; Seesai Yeesoonsang; Surichai Bilheem; Laura Rozek; Imjai Chitapanarux; Donsuk Pongnikorn; Karnchana Daoprasert; Patravoot Vatanasapt; Krittika Suwanrungruang; Rafael Meza
Journal:  J Glob Oncol       Date:  2018-08

Review 7.  Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.

Authors:  Yijia Guo; Jun Song; Yanru Wang; Letian Huang; Li Sun; Jianzhu Zhao; Shuling Zhang; Wei Jing; Jietao Ma; Chengbo Han
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

8.  Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.

Authors:  Piyada Sitthideatphaiboon; Chinachote Teerapakpinyo; Krittiya Korphaisarn; Nophol Leelayuwatanakul; Nopporn Pornpatrananrak; Naravat Poungvarin; Poonchavist Chantranuwat; Shanop Shuangshoti; Chatchawit Aporntewan; Wariya Chintanapakdee; Virote Sriuranpong; Chanida Vinayanuwattikun
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.379

9.  Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.

Authors:  Katsuhiro Masago; Yosuke Togashi; Masahide Fukudo; Tomohiro Terada; Kaoru Irisa; Yuichi Sakamori; Shiro Fujita; Young Hak Kim; Tadashi Mio; Ken-Ichi Inui; Michiaki Mishima
Journal:  Case Rep Oncol       Date:  2010-04-22

10.  The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study.

Authors:  Christian Boch; Jens Kollmeier; Andreas Roth; Susann Stephan-Falkenau; Daniel Misch; Wolfram Grüning; Torsten Thomas Bauer; Thomas Mairinger
Journal:  BMJ Open       Date:  2013-04-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.